Etaracizumab, formerly referred to as MEDI523 and later LM609, represents a promising strategy in immune therapy. This monoclonal protein is intended to specifically inhibit the activity of complement https://lm609280351.pointblog.net/etaracizumab-a-deep-review-into-medi523-and-lm609-96175781